Sfoglia per Autore
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.
2008-01-01 Cervetti, G; Carulli, Giovanni; Galimberti, Sara; Azzara', Antonio; Cannizzo, Elisa; Buda, Gabriele; Orciuolo, E; Petrini, Mario
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines
2008-01-01 Galimberti, Sara; Canestraro, Martina; Khan, R; Buda, Gabriele; Orciuolo, E; Guerrini, Francesca; Fazzi, R; Maffei, Riccardo; Marasca, R; Petrini, Mario
Unusual association of endometrial cancer and multiple myeloma
2008-01-01 Buda, Gabriele; Orciuolo, E; Galimberti, Sara; Petrini, Mario; Maggini, Valentina; Barale, Roberto; Rossi, ANNA MARIA
MDR1 modulates apoptosis in CD34+ leukemic cells
2008-01-01 Buda, Gabriele; Orciuolo, E; Maggini, Valentina; Galimberti, Sara; Barale, Roberto; Rossi, ANNA MARIA; Petrini, Mario
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas
2008-01-01 Carulli, Giovanni; Cannizzo, Elisa; Zucca, A; Buda, Gabriele; Orciuolo, E; Marini, Alessandra; Petrini, Mario
TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib
2008-01-01 Buda, G; Martino, A; Maggini, V; Orciuolo, E; Galimberti, Sara; Gentile, M; Brunori, M; Morabito, F; Rossi, Am; Petrini, M.
Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk
2008-01-01 Maggini, Valentina; Buda, Gabriele; Galimberti, Sara; Martino, A; Orciuolo, E; Morabito, F; Bono, R; Barale, Roberto; Petrini, Mario; Rossi, ANNA MARIA
Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia.
2008-01-01 Orciuolo, E; Buda, Gabriele; Galimberti, Sara; Cervetti, G; Cecconi, N; Papineschi, Federico; Petrini, Mario
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE
2008-01-01 Galimberti, Sara; Cecconi, N; Cervetti, G; Buda, G; Orciuolo, E; Papineschi, Federico; Caracciolo, F; Benedetti, E; Petrini, Mario
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines
2008-01-01 Galimberti, Sara; Canestraro, Martina; Khan, R; Buda, Gabriele; Orciuolo, E; Guerrini, Francesca; Fazzi, R; Maffei, R; Marasca, R; Petrini, Mario
Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression.
2009-01-01 Cannizzo, E; Carulli, Giovanni; Buda, G; Zucca, A; Azzara', Antonio; Orciuolo, E; Petrini, Mario
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma
2009-01-01 Buda, Gabriele; Martino, A; Maggini, Valentina; Orciuolo, E; Galimberti, Sara; Gentile, M; Morabito, F; Antognoni, F; Brunori, M; Barale, Roberto; Rossi, ANNA MARIA; Petrini, Mario
The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience.
2009-01-01 Pelosini, M; Caracciolo, F; Galimberti, Sara; Benedetti, E; Papineschi, Federico; Orciuolo, E; Buda, G; Petrini, Mario
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis.
2009-01-01 Pelosini, M; Baronti, F; Caracciolo, F; Galimberti, Sara; Benedetti, E; Papineschi, Federico; Orciuolo, E; Buda, G; Starita, A; Petrini, Mario
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13.
2009-01-01 Cervetti, G; Galimberti, Sara; Sordi, E; Buda, Gabriele; Orciuolo, E; Cecconi, N; Petrini, Mario
Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis.
2009-01-01 Pelosini, M; Baronti, F; Caracciolo, F; Galimberti, Sara; Benedetti, E; Papineschi, Federico; Orciuolo, E; Buda, G; Starita, A; Petrini, Mario
Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.
2009-01-01 Buda, Gabriele; Martino, A; Orciuolo, E; Lupia, A; Galimberti, Sara; Gentile, M; Morabito, F; Rossi, ANNA MARIA; Petrini, Mario
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA
2009-01-01 Galimberti, Sara; Nagy, B; Palumbo, Ga; Buda, G; Orciuolo, E; Melosi, A; Lambelet, P; Petrini, Mario
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma
2009-01-01 Buda, Gabriele; Orciuolo, E; Galimberti, Sara; Cecconi, N; Petrini, Mario
CD23 expression in plasma cell leukaemia
2010-01-01 Buda, G; Carulli, Giovanni; Orciuolo, E; Cannizzo, E; Pelosini, M; Galimberti, Sara; Petrini, Mario
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. | 1-gen-2008 | Cervetti, G; Carulli, Giovanni; Galimberti, Sara; Azzara', Antonio; Cannizzo, Elisa; Buda, Gabriele; Orciuolo, E; Petrini, Mario | |
| Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines | 1-gen-2008 | Galimberti, Sara; Canestraro, Martina; Khan, R; Buda, Gabriele; Orciuolo, E; Guerrini, Francesca; Fazzi, R; Maffei, Riccardo; Marasca, R; Petrini, Mario | |
| Unusual association of endometrial cancer and multiple myeloma | 1-gen-2008 | Buda, Gabriele; Orciuolo, E; Galimberti, Sara; Petrini, Mario; Maggini, Valentina; Barale, Roberto; Rossi, ANNA MARIA | |
| MDR1 modulates apoptosis in CD34+ leukemic cells | 1-gen-2008 | Buda, Gabriele; Orciuolo, E; Maggini, Valentina; Galimberti, Sara; Barale, Roberto; Rossi, ANNA MARIA; Petrini, Mario | |
| CD45 expression in low-grade B-cell non-Hodgkin's lymphomas | 1-gen-2008 | Carulli, Giovanni; Cannizzo, Elisa; Zucca, A; Buda, Gabriele; Orciuolo, E; Marini, Alessandra; Petrini, Mario | |
| TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib | 1-gen-2008 | Buda, G; Martino, A; Maggini, V; Orciuolo, E; Galimberti, Sara; Gentile, M; Brunori, M; Morabito, F; Rossi, Am; Petrini, M. | |
| Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk | 1-gen-2008 | Maggini, Valentina; Buda, Gabriele; Galimberti, Sara; Martino, A; Orciuolo, E; Morabito, F; Bono, R; Barale, Roberto; Petrini, Mario; Rossi, ANNA MARIA | |
| Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. | 1-gen-2008 | Orciuolo, E; Buda, Gabriele; Galimberti, Sara; Cervetti, G; Cecconi, N; Papineschi, Federico; Petrini, Mario | |
| CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE | 1-gen-2008 | Galimberti, Sara; Cecconi, N; Cervetti, G; Buda, G; Orciuolo, E; Papineschi, Federico; Caracciolo, F; Benedetti, E; Petrini, Mario | |
| Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines | 1-gen-2008 | Galimberti, Sara; Canestraro, Martina; Khan, R; Buda, Gabriele; Orciuolo, E; Guerrini, Francesca; Fazzi, R; Maffei, R; Marasca, R; Petrini, Mario | |
| Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression. | 1-gen-2009 | Cannizzo, E; Carulli, Giovanni; Buda, G; Zucca, A; Azzara', Antonio; Orciuolo, E; Petrini, Mario | |
| MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma | 1-gen-2009 | Buda, Gabriele; Martino, A; Maggini, Valentina; Orciuolo, E; Galimberti, Sara; Gentile, M; Morabito, F; Antognoni, F; Brunori, M; Barale, Roberto; Rossi, ANNA MARIA; Petrini, Mario | |
| The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience. | 1-gen-2009 | Pelosini, M; Caracciolo, F; Galimberti, Sara; Benedetti, E; Papineschi, Federico; Orciuolo, E; Buda, G; Petrini, Mario | |
| Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. | 1-gen-2009 | Pelosini, M; Baronti, F; Caracciolo, F; Galimberti, Sara; Benedetti, E; Papineschi, Federico; Orciuolo, E; Buda, G; Starita, A; Petrini, Mario | |
| Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. | 1-gen-2009 | Cervetti, G; Galimberti, Sara; Sordi, E; Buda, Gabriele; Orciuolo, E; Cecconi, N; Petrini, Mario | |
| Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis. | 1-gen-2009 | Pelosini, M; Baronti, F; Caracciolo, F; Galimberti, Sara; Benedetti, E; Papineschi, Federico; Orciuolo, E; Buda, G; Starita, A; Petrini, Mario | |
| Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B. | 1-gen-2009 | Buda, Gabriele; Martino, A; Orciuolo, E; Lupia, A; Galimberti, Sara; Gentile, M; Morabito, F; Rossi, ANNA MARIA; Petrini, Mario | |
| VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA | 1-gen-2009 | Galimberti, Sara; Nagy, B; Palumbo, Ga; Buda, G; Orciuolo, E; Melosi, A; Lambelet, P; Petrini, Mario | |
| Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma | 1-gen-2009 | Buda, Gabriele; Orciuolo, E; Galimberti, Sara; Cecconi, N; Petrini, Mario | |
| CD23 expression in plasma cell leukaemia | 1-gen-2010 | Buda, G; Carulli, Giovanni; Orciuolo, E; Cannizzo, E; Pelosini, M; Galimberti, Sara; Petrini, Mario |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile